PEDIATRICS Vol. 65 No. 3 March 1980, pp. 673
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mitchell, R. A.
Right arrow Articles by Arcinue, E. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mitchell, R. A.
Right arrow Articles by Arcinue, E. L.

Hepatic Monoamine Oxidase Deficiency in Reye Syndrome

Robert A. Mitchell PhD1 and Edgardo L. Arcinue MD2

1 Department of Biochemistry, Wayne State University School of Medicine, Detroit, MI 48201
2 Department of Pediatrics, Wayne State University School of Medicine and Reye Syndrome Study Center, Children's Hospital of Michigan, Detroit, MI 48201

Faraj et al1 recently reported a positive correlation between plasma tyramine levels and the number of days in coma, for patients with biopsy-proven Reye's syndrome. They suggested that the mitochondrial injury might have a disruptive effect upon hepatic monoamine oxidase, with a subsequent decrease in clearance of tyramine. We have reached a similar conclusion on the possible role of tyramine in the development of the encephalopathy, based on the finding that the hepatic monoamine oxidase activity was reduced about 60% in stage V Reye's syndrome patients.